A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Novartis Pharmaceuticals
- Número de teléfono: +41613241111
- Correo electrónico: novartis.email@novartis.com
Copia de seguridad de contactos de estudio
- Nombre: Novartis Pharmaceuticals
Ubicaciones de estudio
-
-
New Jersey
-
East Hanover, New Jersey, Estados Unidos, 07936
- Reclutamiento
- Novartis
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion criteria:
- Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
- Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
- Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
- Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
- Age ≥18 years at index.
Exclusion criteria:
• None.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Número de grupos/cohortes
Cohortes e Intervenciones
Grupo / CohorteGrupo / Cohorte |
|---|
|
Overall mCRPC Cohort
Adult patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in PRECISION.
|
|
mCRPC Progression Subgroup
A subgroup of the Overall mCRPC Cohort.
Patients with evidence of progression on or after 177Lu-PSMA-617 treatment.
|
|
≥1 Subsequent Systemic Therapy Subgroup
A subgroup of the Overall mCRPC Cohort.
Patients who initiate ≥1 post-index systemic therapy.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Patients by Number of Lines of Therapy (LOTs) Between mCRPC Diagnosis and Index Date
Periodo de tiempo: Baseline
|
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
|
Baseline
|
|
Number of Patients by Number and Type of Prior Therapies Indicated for Advanced Prostate Cancer (PC)
Periodo de tiempo: Baseline
|
Number of patients by number and type of prior ARPI, taxane, 177Lu-PSMA-617, and other therapies indicated for advanced PC.
|
Baseline
|
|
Number of Patients by Number of Prostate-specific Membrane Antigen (PSMA) Scans
Periodo de tiempo: Baseline up to approximately 5 years
|
Baseline up to approximately 5 years
|
|
|
Number of Patients by Timing of PSMA Scans
Periodo de tiempo: Baseline up to approximately 5 years
|
Timing of scans is categorized as pre-mCRPC diagnosis, post-mCRPC diagnosis but pre-index date, and post-index date.
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
|
Baseline up to approximately 5 years
|
|
Number of Patients by Number of Post-index LOTs
Periodo de tiempo: Up to approximately 5 years
|
Up to approximately 5 years
|
|
|
Number of Patients by Type of Therapy at Each Post-index LOT
Periodo de tiempo: Up to approximately 5 years
|
Up to approximately 5 years
|
|
|
Time From Index Date to Next Therapy Initiation
Periodo de tiempo: Up to approximately 5 years
|
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
|
Up to approximately 5 years
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Años
Periodo de tiempo: Base
|
Base
|
|
|
Number of Patients by Patient Characteristics
Periodo de tiempo: Baseline
|
Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.
|
Baseline
|
|
Progression-free Survival (PFS) From Index Date
Periodo de tiempo: Up to approximately 5 years
|
Time from the applicable index date until progression or death from any cause.
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
|
Up to approximately 5 years
|
|
PFS From Initiation of First Post-index Therapy, in Patients With ≥1 Post-index Therapy
Periodo de tiempo: Up to approximately 5 years
|
Time from the initiation of first post-index therapy until progression or death from any cause.
|
Up to approximately 5 years
|
|
Overall Survival (OS) From Index Date
Periodo de tiempo: Up to approximately 5 years
|
Time from the applicable index date until death from any cause.
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
|
Up to approximately 5 years
|
|
OS From Initiation of First Post-index Therapy, in Those With ≥1 Post-index Therapy
Periodo de tiempo: Up to approximately 5 years
|
Time from initiation of first post-index therapy until death from any cause.
|
Up to approximately 5 years
|
|
Among Patients With ≥1 Post-index Therapy, Number of Patients With a Reduction in PSA Level
Periodo de tiempo: Up to approximately 5 years
|
Reduction in PSA level categorized as follows:
|
Up to approximately 5 years
|
|
Among Patients With ≥1 Post-index Therapy, Number of Patients With PSA <0.2 ng/mL on First Post-index Therapy
Periodo de tiempo: Up to approximately 5 years
|
Up to approximately 5 years
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Neoplasias prostáticas resistentes a la castración
Otros números de identificación del estudio
Otros números de identificación del estudio
- CAAA617A1US30
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .